| 摘要 |
Disclosed is the use of an anti-VEGF antibody, or antigen binding fragment thereof, that blocks VEGF binding to VEGFR1 and VEGFR2, in the manufacture of a medicament for preventing occurrence or recurrence of a benign, pre-cancerous, or non-metastatic cancer in a subject, wherein the subject has a family history of cancer, polyps, or an inherited cancer syndrome, and wherein the subject does not have cancer. |
